Sandira Segaram
Internal Medicine · Hackettstown, NJNPI 1508813346
Payments from drug & device makers
Across 417 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Astellas Pharma US Inc$586
- Dexcom, Inc.$459
- Boehringer Ingelheim$410
- Lilly USA, LLC$399
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,46594%
- Education$4606%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,517 |
| Novo Nordisk | 88 | $1,189 |
| Astellas Pharma US Inc | 21 | $586 |
| Dexcom, Inc. | 5 | $459 |
| Boehringer Ingelheim | 15 | $410 |
| Lilly USA, LLC | 25 | $399 |
| Bayer | 20 | $334 |
| Amarin Pharma, Inc. | 25 | $314 |
| Sumitomo Pharma America, Inc. | 17 | $281 |
| Sanofi-aventis U.S. LLC | 9 | $276 |
| Amgen | 9 | $231 |
| Sunovion Pharmaceuticals Inc. | 15 | $214 |
| Exact Sciences | 8 | $169 |
| Pfizer | 12 | $162 |
| Otsuka America Pharmaceutical, Inc. | 9 | $148 |
| AbbVie | 3 | $147 |
| GSK | 10 | $143 |
| Merck | 8 | $113 |
| Eisai Inc. | 7 | $96 |
| Biogen | 4 | $84 |
| IBSA Pharma Inc. | 6 | $75 |
| Johnson & Johnson | 5 | $64 |
| Embecta Corp. | 1 | $63 |
| Lundbeck LLC | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 4 | $61 |
| Avanir Pharmaceuticals, Inc. | 4 | $56 |
| Supernus Pharmaceuticals, Inc. | 4 | $55 |
| Novartis | 4 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Nevro Corp. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$530
- FARXIGA$400
- DEXCOM G6 TRANSMITTER$239
- AIRSUPRA$171
- OFEV$125
- Repatha$120
- QULIPTA$120
- UBRELVY$120
- FASENRA$111
- BREZTRI AEROSPHERE$111
- SYMBICORT$111
- SOLIQUA 100/33$107
How this compares
$7,925 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 303 | $191,583 |
| OzempicSemaglutide | 64 | $102,651 |
| JanuviaSitagliptin Phosphate | 64 | $52,261 |
| JardianceEmpagliflozin | 54 | $51,595 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $46,786 |
| XareltoRivaroxaban | 48 | $30,388 |
| MyrbetriqMirabegron | 34 | $17,364 |
| SecuadoAsenapine | 11 | $16,131 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $13,830 |
| EntrestoSacubitril/Valsartan | 19 | $12,535 |
| FarxigaDapagliflozin Propanediol | 16 | $12,526 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,741 |
| FiaspInsulin Aspart (Niacinamide) | 36 | $10,975 |
| Atorvastatin Calcium | 761 | $10,251 |
| RytaryCarbidopa/Levodopa | 11 | $9,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $162 | $191,583303 claims |
| Novo NordiskOzempic, Fiasp | $1,189 | $113,626100 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $410 | $66,16576 claims |
| MerckJanuvia, Janumet | $113 | $66,09179 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $143 | $55,37279 claims |
| Johnson & JohnsonXarelto | $64 | $30,38848 claims |
| Astellas Pharma US IncMyrbetriq | $586 | $17,36434 claims |
| NovartisEntresto | $53 | $12,53519 claims |
| AstraZenecaFarxiga | $1,517 | $12,52616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Hackettstown
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.